Iverson Sponsors Wounded Warriors Golf Tournament
Coming Soon: Methylation Genotype Profile
Thomas Siggia Joins Iverson's Board of Directors
Iverson's Fall 2011 Newsletter
Iverson's Spring 2011 Newsletter
Press Release: WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
Leroy Hood, MD, PhD Joins Iverson's Board of Directors
Matthew J. Price, MD, FACC, FSCAI (Director, Cardiac Catheterization Laboratory, Scripps Clinic & Assistant Professor, Scripps Translational Science Institute) joins Iverson Genetics' Medical Advisory Council
Warfarin Study Approved by Medicare
South Carolina Lab Launched
Iverson Attended the 19th Annual Alabama Chapter ACC Conference June 4-6, 2010
Monisha Pujari's White Papers on Warfarin and Clopidogrel Released
Iverson's Network Lab opens at the Morehouse School of Medicine in Atlanta, GA
Iverson Bothell Lab accredited by CAP (College of American Pathologists)
Iverson attended The 30th Annual SWAHAP (the Southwest Association of Hispanic American Physicians) Medical Education Congress in El Paso, TX on Nov. 13-14.
Iverson attended the 5th Annual Burrill Personalized Medicine Meeting at the Mission Bay Conference Center at UC San Francisco on Nov. 9-10
Iverson's International Growth
Iverson attended the 2009 Fall MedAxiom Conference in Monarch Beach, CA, Sept 23rd - 25th
Iverson attended the 2009 Fall Meeting for the Texas Medical Group Management Association
Iverson Partners With Leading Hospitals to Address Warfarin Pharmacogenetic Testing
Estrogen Metabolism Panel Coming Soon!
Iverson's Lab Participating in Blood vs. Buccal Swab Study
Iverson National Coverage Update
|
|
|
Iverson Sponsors the Wounded Warriors Golf Tournament
Troy, NY, July 2nd, 2012 - Iverson was pleased to be involved as a sponsor of the Wounded Warriors Golf Tournament in Troy, New York. General Martin Dempsey the 18th and current Chairman of the Joint Chiefs of Staff were in attendance.
Click here to see the Iverson team.
Coming Soon: Methylation Genotype Profile
BOTHELL, WA, January 17th, 2012 - Iverson is pleased to announce the introduction of a new test -- the Methylation Genotype Profile. A wide variety of biochemical pathways require the addition of a methyl group (a single carbon atom with 3 hydrogen atoms attached to the carbon atom). This entire process is controlled by a complex of different methylation-related enzymes (e.g. MTHFR, MTRR, COMT, BHMT, CBS, MAO, NOS, VDR, SHMT, etc). Each of these enzymes is synthesized according to gene codes in the DNA. Each of the genes (alleles) has the same name as the enzyme that it codes for. However, there are common genetic variations of each of these alleles caused by minor changes in the code, usually a single base change in the code sequence. The "variants"of the normal genes produce enzymes with limited or almost no ability to catalyze their specific biochemical pathways.
Presence of methylation gene variants has been associated with a wide variety of disease conditions: cardiovascular, cancer, depression, loss of anti-oxidant capacity, and other abnormal medical conditions.
Stay tuned for more information.
Thomas Siggia Joins Iverson's Board of Directors
BOTHELL, WA, January 5th, 2012 - Iverson is pleased to welcome Thomas Siggia to our Board of Directors. Mr. Siggia is the former Vice President Market Operations for IBM's STG's worldwide strategic sales initiatives and operations. Mr. Siggia joined IBM in 1976 and for 35 years served in numerous management and executive positions in areas including sales, finance, planning and operations. He retired August 31, 2011. During his tenure with IBM, he held numerous sales, finance, and operations positions in from 1976-1994. He began working in the America's State and Local Government Group in 1995 and held the position of IBM Business Partner Business Unit Executive from 1997 to 1999. In 2000, he was appointed Director, Storage Group and in 2003 became Vice President of Worldwide Sales Operations and Strategic Initiatives for the Systems and Technology Group. He was appointed Vice President, Global Public Sector in January, 2005 and in 2008 assumed his current position as Worldwide Vice President of Market Operations, STG System Sales. Born in Brooklyn, Mr. Siggia was raised in Albany, New York. He worked for IBM in the Albany area from 1976 to 1979 and then traveled on assignment to IBM offices in Rhode Island, Boston, and Longmeadow, Massachusetts, until he returned to IBM's Albany office in 1991. A 1976 graduate of Siena College with a Bachelor of Science degree in marketing, Mr. Siggia has been a member of the board of the Troy Country Club since 2008 and the board of the Cystic Fibrosis Foundation, North East Chapter, since 2007.
Click here to see the full board of directors.
Iverson's Fall Newsletter
Iverson recently released it's Fall Newsletter featuring the latest happenings on the company.
Click here to view the full document.
Iverson's Spring Newsletter
Iverson recently released it's Spring Newsletter featuring the latest happenings on the company.
Click here to view the full document.
Press Release: WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
First major personalized medicine study authorized by Centers for Medicare & Medicaid Services may drive reimbursement based on improved patient safety, reduced healthcare costs.
Bothell, WA, March 1, 2011 -- Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) was initiated in major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events. Warfarin, the most commonly prescribed blood thinner worldwide, causes up to 100,000 serious and unnecessary adverse events every year, including thousands of deaths. Studies have shown that DNA testing can dramatically improve the safety and effectiveness of warfarin, with estimated savings to the U.S. healthcare system of approximately $1.1 billion...
Click here to read the full press release.
Leroy Hood, MD, PhD Joins Iverson's Board of Directors
BOTHELL,
WA, February 16th, 2011 - Iverson is pleased to welcome Dr. Leroy Hood
to our Board of Directors. Dr. Hood is the President and co-founder of the Institute for Systems Biology in Seattle. He is is a pioneer in systems approaches to biology and medicine. Dr. Hood's research has focused on the study of molecular immunology, biotechnology and genomics. His professional career began at Caltech, where he and his colleagues developed the DNA gene sequencer and synthesizer and the protein synthesizer and sequencer--four instruments that paved the way for the successful mapping of the human genome and lead to his receiving this year's prestigious Russ Prize, awarded by the Academy of Engineering. A pillar in the biotechnology field, Dr. Hood has played a role in founding more than fourteen biotechnology companies, including Amgen, Applied Biosystems, Darwin, The Accelerator and Integrated Diagnostics. He is a member of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine, one of only 7 people in the world to be elected to all three academies. He is also a member of the American Philosophical Society and a Fellow of American Academy of Arts and Sciences. His work has been widely published and he has coauthored numerous textbooks in biochemistry, immunology, molecular biology and genetics, as well as a popular book on the human genome project, The Code of Codes. He is the recipient of numerous awards, including the Lasker Award, the Kyoto Prize and the Heinz Award in Technology. Dr. Hood has also received 17 honorary degrees from universities in the US and other countries.
Click here to see the full board of directors.
Matthew J. Price, MD, FACC, FSCAI (Director, Cardiac Catheterization Laboratory, Scripps Clinic & Assistant Professor, Scripps Translational Science Institute) joins Iverson Genetics' Medical Advisory Council
BOTHELL,
WA, August, 2010 - Iverson is pleased to welcome Dr. Matthew J Price to our Medical Advisory Council. Dr. Price is an interventional cardiologist and currently serves as Director of the Cardiac Catheterization Laboratory in the Cardiovascular Division of Scripps Clinic and Assistant Professor at the Scripps Translational Science Institute, both in La Jolla, California. He received his bachelor's degree with distinction in all subjects from Cornell University, in Ithaca, New York. He then received his medical degree from the University of California, Los Angeles and served as resident in internal medicine at the UCLA Center for Health Sciences. After completing his cardiology fellowship at the Cedars Sinai Medical Center in Los Angeles, California where he was named chief fellow, Dr. Price completed a fellowship in interventional cardiology at Scripps Clinic, where he joined the faculty of the Cardiovascular division. Dr. Price has published numerous papers on high risk percutaneous coronary intervention, on drug-eluting stents, and on the impact of personalized anti-platelet therapy on outcomes after stent implantation. He is involved in the leadership of several clinical trials of anti-platelet therapy, and is Principal Investigator of GRAVITAS, a mulitcenter, randomized trial of individualized antiplatelet therapy to reduce thrombotic events after percutaneous coronary intervention with drug-eluting stents. He is also a busy clinical interventionalist, performing both coronary procedures and also specializing in percutaneous approaches to structural and congenital heart disease. Dr. Price serves as contributing editor to Reviews in Cardiovascular Medicine and an ad hoc reviewer for several leading journals, including American Heart Journal, American Journal of Cardiology, Circulation, and the Journal of the American College of Cardiology.
Click here to see the full board.
Warfarin Study Approved by Medicare
BOTHELL, WA, June 30, 2010 - Iverson Genetics today announced that they have received approval from CMS to conduct the WARFARIN clinical study. The two (2) year study addresses whether using warfarin-related pharmacogenetic information in calculating doses will change the rate of related adverse events, including major hemorrhage and thromboembolic events, when compared to warfarin doses calculated without pharmacogenetic data. The multicenter, randomized, blinded, parallel-group study is being led by Principal Investigator Dr. Elizabeth Ofili, MD, Director of Clinical Research and Associate Dean for Clincal Research at Morehouse School of Medicine.
Click here to read the full press release.
South Carolina Lab Launched
June 29, 2010 - Iverson
Genetic Diagnostics opened a new east coast testing facility in
Charleston, South Carolina. Testing on the east coast provides a 3 hour
turnaround time advantage over our west coast facility. This is
especially important in genetic testing to guide drug therapy for
critical drugs such as Warfarin and Plavix. The west coast facility
remains the main center for reporting, administrative activities, and
for research and development. Specimens for the new Warfarin outcome
study will be analyzed at our other east coast laboratory, located at
the Morehouse School of Medicine in Atlanta, Georgia.
Iverson Attended the 19th Annual Alabama Chapter ACC Conference June 4-6, 2010
Iverson recently attended the 19th Annual
Alabama Chapter of the American College of Cardiology Conference June
4-6, 2010. The American College of Cardiology is leading the way to
optimal cardiovascular care and disease prevention. The College is a
39,000 member nonprofit medical professional society and bestows the
credential Fellow of the American College of Cardiology upon physicians
who meet its stringent qualifications. The College is a leader in the
formulation of health policy, standards and guidelines, and is a staunch
supporter of cardiovascular research. The ACC provides professional
education and operates national registries for the measurement and
improvement of quality care.
Click here
to visit their website.
Iverson's Network Lab opens at the Morehouse School of Medicine in Atlanta, GA
Iverson recently opened a network lab at the Morehouse School of Medicine in Atlanta, GA. Iverson CEO, Dean Sproles released a statement saying, "Personal, gene-based information is the next wave of optimizing therapy and enhancing personal wellness for patients. This genetic testing laboratory at Morehouse School of Medicine will provide physicians and other healthcare providers in Georgia and around the nation with more specific gene-based information to optimize the care of their patients. For example, gene-based information from this lab will help physicians understand how a patient may respond to a specific drug and effectively introduce clinically relevant genetic testing into mainstream medicine."
Click here to read the full press release.
Morehouse School of Medicine
Iverson Bothell Lab accredited by CAP (College of American Pathologists)
On August 31st, two doctors from the Molecular Pathology Laboratory at Creighton University Medical School in Nebraska visited our headquarters in Bothell for our first College of American Pathologists (CAP) laboratory inspection. Although Iverson has been certified for several years under the federal CLIA inspection and licensure program, Iverson elected to have a CAP inspection as well. CAP's mission is more than regulatory, it is also educational. CAP inspections aim to provide interaction between the inspectors, who are functioning lab directors or technicians, and those being inspected, in order to share ideas for laboratory improvement. We had a successful inspection and obtained ideas for improvement. As of October 12th, 2009 Iverson Genetic Diagnostics, Inc. is CAP certified. Congratulations to Iverson and the amazing lab team led by Dr. Laurance Ferreri in Bothell, WA.
Click here to learn about CAP.
Iverson attended The 30th Annual SWAHAP (the Southwest Association of Hispanic American Physicians) Medical Education Congress in El Paso, TX on Nov. 13-14.
Iverson recently attended a conference hosted by the Southwest Association of Hispanic American Physicians, in joint sponsorship with Sierra Providence Health Network. Over 200 physicians, over 100 nurses and other healthcare professionals throughout West Texas and New Mexico were in attendance.
Click here to learn more about the SWAHAP conference.
Iverson attended the 5th Annual Burrill Personalized Medicine Meeting at the Mission Bay Conference Center at UC San Francisco on Nov. 9-10
We recently attended the 5th Annual Burrill Personalized Medicine Meeting, a two-day event, which encompasses detailed discussions on the spectrum of personalized medicine from prediction to prevention. The event provided attendees with a detailed 'window'into the emerging personalized medicine world. This year brought together researchers, drug developers, diagnostics manufacturers, clinicians, payors, investors, public policy experts, medical ethicists and patients for a fascinating and instructive set of conversations focusing on the impact that broader healthcare reform will have on personalized medicine.
Click here to visit the conference website.
Iverson's International Growth
Iverson is seeking international patent protection for our Broad-Based Gene Transcript Test in China, Canada, and the EU. Also, paperwork is in progress for regulatory approval permits to have specimens cross the border from Canada, Mexico, Puerto Rico and Barbados.
Iverson attended the 2009 Fall MedAxiom Conference in Monarch Beach, CA Sept 23rd - 25th
Iverson is attended the 2009 Fall MedAxiom Conference in Monarch Beach, CA, Sept.23rd - 25th, 2009. MedAxiom is one of the most valuable resources a cardiology practice can have. They are a comprehensive subscription-based service provider and information resource exclusively for cardiology practices. Their network has grown to over 300 practices representing 5,400 physicians across the U.S. MedAxiom is a community of cardiology practice executives, administrative leaders, physicians and business office teams that strive to be more effective and efficient through sharing of operational practice data, best practice business strategies, positive and negative experiences as well as insights into the future of cardiology. MedAxiom's services are anchored by cardiology-specific comparative statistical analysis and benchmark reporting on financial, operational, and clinical functions within the practice. They collect well over 600 data points covering all facets of cardiology practice operations.
Click here to learn more.
Iverson attended the 2009 Fall Meeting for the Texas Medical
Group Management Association
Iverson
attended the 2009 Fall Texas Medical Group Management Association in
Austin, TX on September 3rd and 4th.The Texas Medical Group Management
Association is a professional association of medical practice
administrators founded in 1973, representing over 400 practice
administrators in Texas. Texas MGMA has over 500 members representing
over 374 medical practices. Approximately 50% of members work in
practices that are 10+ physicians. Approximately 50% of members work in
practices with 10 physicians or less.
Click here to learn more.
Iverson Partners With Leading Hospitals to Address Warfarin Pharmacogenetic Testing
In a collaborative effort, Iverson Genetic Diagnostics, Inc. has partnered with leading decision makers in participating hospital networks to establish a steering committee to develop a protocol and create a clinical trial aimed at addressing CMS's proposal for Warfarin pharmacogenetic testing. Hospital networks nationwide will have the opportunity to participate, and collect data to identify the primary outcomes of warfarin sensitivity testing and personalized dose recommendations for individuals who are initiating warfarin therapy.
Estrogen Metabolism Panel Coming Soon!
Iverson is developing an Estrogen Metabolism Panel to evaluate how estrogen is processed in the body prior to prescribing hormone replacement therapy. The estimated product release date is scheduled for September 1st, 2009. Additionally, a comprehensive Women's Health Initiative Panel which will follow. The test will include specific genetic variants associated with women's health concerns, such as estrogen metabolism, Tamoxifen responsiveness, Thrombosis risk, and HPV risk. Release date is TBD.
Iverson's Lab Participating in Blood vs. Buccal Swab Study
Iverson's Laboratory has collected 60 samples to provide information on the efficacy of the non-invasive buccal swab collection technique. The samples will be run on the Osmetech Warfarin extended panel assay, and include a broad range of ages, ethnic backgrounds, and male and female participants.
Iverson National Coverage Update
Iverson has extended its list of credentialed national insurance providers and is in the process of becoming credentialed with all major hospital systems in the U.S.
|
|
|
